Navigation Links
Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
Date:3/1/2012

TORONTO, March 1, 2012 /PRNewswire/ -- Modern Mobility Aids, Inc. (the "Company"), headquartered in Nevada, USA (OTC: MDRM), has revised its agreement to acquire of all the common stock of Lumigene Technologies Inc. ("Lumigene") and expects to complete the transaction by March 31, 2012.

Lumigene is a private Canadian company engaged in developing molecular diagnostic products for the rapid and accurate detection of a number of specific pathogens and infectious diseases. With the acquisition of Lumigene, the Company will address the ever-increasing demand for less time-consuming and more cost-effective methods of DNA testing and diagnosis of infectious diseases at point of care. (Current testing methods typically require several day's work by highly trained technicians in an off-site laboratory.)

Mohamed K. Karatella, President and CEO, discussed the largely unmet need to speed up DNA sample preparation in order to obtain immediate and accurate results on site and the user friendly products being developed by Lumigene for this purpose. --- "Staff at hospitals, healthcare clinics and even airports need fast detection of pathogens, infectious diseases and other ailments right at the point of DNA sampling. Delivering the first available solution to produce such reliable results within an hour with Lumigene's automated and economic technology will open up a broad range of applications with a large global market potential. We are also very pleased to welcome Lumigene's highly talented technical team, which will greatly enhance our innovative bioscience research and add strength to our management team also."

Under the revised agreement, the purchase price for Lumigene is largely predicated on the achievement of certain key business, patent and technological milestones.

About Modern Mobility Aids, Inc.

investor@mdrmgroup.com

416 645 8350


'/>"/>
SOURCE Modern Mobility Aids, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology news :

1. European Neandertals were on the verge of extinction even before the arrival of modern humans
2. Modern genetics answers age-old question on Garrods fourth inborn error of metabolism
3. Invasion of genomic parasites triggered modern mammalian pregnancy
4. Evolutions past is modern humans present
5. Researchers discover oldest evidence of nails in modern primates
6. Modern fish communities live fast and die young
7. Modern EU agriculture jeopardizes biodiversity in new member states
8. Mummies tell history of a modern plague
9. Low-cost molecular medicine should be included in modern eye physicians tool kit
10. Living dinosaurs: The evolutionary history of modern birds
11. Paleontologists audition modern examples of ancient behavior
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by ... Global Forecast to 2022", published by MarketsandMarkets, the market is expected to be ... 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 23, 2017 Research and Markets has ... report to their offering. ... The Global Market for Bioproducts ... 2016 at a CAGR of 8.9%, This ... bioproducts into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
Breaking Biology Technology: